Joint Pain Injections Market - by Injection type, By Joint type, By End-use & Global Forecast, 2023

Description

List of Tables

Joint Pain Injections Market trends are slated to be propelled by 2032 given the elevating demand for knee pain injections worldwide. Knee joint pain injections are deemed to be an ideal product to treat joint pain conditions. A recent evaluation of the Medicare sample database demonstrated that more than 1/3rd of patients with newly identified knee osteoarthritis were treated with at least one intra-articular corticosteroid injection.

Growing demand for joint pain injections for effective and quick treatment of joint inflammation and pain and soft tissue conditions would further strengthen the market outlook over 2023-2032.

Global expansion and product range diversification strategies by prominent market players are slated to have a positive impact on the industry growth. For example, Seikagu launched HyLink in Taiwan. The product is an intra-articular single injection viscosupplement for the treatment of knee osteoarthritis. It has been made of Seikagaku's exceptional crosslinking technology.

The global joint pain injections industry has been bifurcated on the basis of injection type, joint type, end-use, and region.

Considering the injection type, the platelet rich plasma segment is predicted to amass considerable gains through 2032, attributable to its ability to provide optimum relief from pain and swelling and freedom of movement for a longer time. According to a study, the platelet rich plasma injections have depicted promising results in achieving pain reduction and improved function in patients suffering from OA. Besides, the injections also delay the need for knee replacement. Such factors would impel the segmental growth prospects in the ensuing years.

With regard to the joint type, ankle and hip segment would draw massive traction due to the rising incidence rate of ankle and hip arthritis. As per a recent survey, ankle osteoarthritis currently affects 1% of the global population, with an estimated frequency of 30 cases per 100,000 people. Moreover, advancements in joint pain injections that deliver ample benefits in treating ankle and hip joint pain and the launch of new products by prominent companies in the business sphere would potentially drive the market growth between 2023-2032.

Based on the end-use, clinics are estimated to gain major impetus in the global pain injections market fueled by the mounting preference of people for minimally invasive surgical procedures in these settings. Pivotal factors like the availability of a broad range of orthopedic procedures, incorporation of advanced technology for surgeries, and deliverance of high-quality services across clinics would add to the booming market curve. The segmental revenues are projected to surge beyond $2.5 billion by 2032.

Geographically, the sale of joint pain injections is estimated to gain momentum in Europe in the coming years on grounds of the growing healthcare expenditure, increasing geriatric population, and surging OA incidences in the region. The adoption of novel strategies by various central governments to promote access to orthopedic diseases treatments would complement the regional market growth over the review timeline.

Product Code: 5403

Chapter 1 Methodology

1.1 Market definition
1.2 Base estimates & working
1.3 Forecast parameters
1.4 Data validation
1.5 Data joint types
- 1.5.1 Secondary
  - 1.5.1.1 Paid joint types
  - 1.5.1.2 Unpaid joint types
- 1.5.2 Primary

Chapter 2 Executive Summary

2.1 Joint pain injection 360 degree synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Form trends
- 2.1.3 Source trends
- 2.1.4 End-use trends
- 2.1.5 Regional trends

Chapter 3 Joint pain injection Industry Insights

3.1 Industry segmentation
3.2 Industry landscape, 2018 - 2032 (USD Million)
3.3 Industry impact factors
- 3.3.1 Growth drivers
  - 3.3.1.1 Growing prevalence of orthopaedic diseases
  - 3.3.1.2 Technological advancements
  - 3.3.1.3 Rising demand for knee pain injections
  - 3.3.1.4 Therapeutics advantages to relieve joint pain & inflammation
- 3.3.2 Industry pitfalls & challenges
  - 3.3.2.1 High cost of joint pain injections
  - 3.3.2.2 Side effects associated with joint pain injections
3.4 Growth potential analysis
- 3.4.1 By injection type
- 3.4.2 By joint type
- 3.4.3 By end-use
3.5 COVID-19 impact analysis
3.6 Porter's analysis
3.7 Competitive landscape, 2022
- 3.7.1 Company matrix analysis, 2022
3.8 PESTEL analysis

Chapter 4 Joint Pain Injections Market, By injection type

4.1 Key segment trends
4.2 Hyaluronic acid injections
- 4.2.1 Market size, by region, 2018 - 2032 (USD Million)
4.3 Corticosteroid injections
- 4.3.1 Market size, by region, 2018 - 2032 (USD Million)
4.4 Platelet rich plasma injections
- 4.4.1 Market size, by region, 2018 - 2032 (USD Million)

Chapter 5 Joint Pain Injections Market, By joint type

5.1 Key segment trends
5.2 Knee
- 5.2.1 Market size, by region, 2018 - 2032 (USD Million)
5.3 Shoulder & elbow
5.4 Ankle & hip
5.5 Others

Chapter 6 Joint Pain Injections Market, By end use

6.1 Key segment trends
6.2 Hospitals
- 6.2.1 Market size, by region, 2018 - 2032 (USD Million)
6.3 Clinics
- 6.3.1 Market size, by region, 2018 - 2032 (USD Million)
6.4 Others
- 6.4.1 Market size, by region, 2018 - 2032 (USD Million)

Chapter 7 Joint Pain Injections Market, By Region

7.1 Key regional trends
7.2 North America
- 7.2.1 Market size, by country, 2018 - 2032 (USD Million)
- 7.2.2 Market size, by injection type, 2018 - 2032 (USD Million)
- 7.2.3 Market size, by joint type, 2018 - 2032 (USD Million)
- 7.2.4 Market size, by end use, 2018 - 2032 (USD Million)
- 7.2.5 U.S.
  - 7.2.5.1 Market size, by country, 2018 - 2032 (USD Million)
  - 7.2.5.2 Market size, by injection type, 2018 - 2032 (USD Million)
  - 7.2.5.3 Market size, by joint type, 2018 - 2032 (USD Million)
  - 7.2.5.4 Market size, by end use, 2018 - 2032 (USD Million)
- 7.2.6 Canada
  - 7.2.6.1 Market size, by country, 2018 - 2032 (USD Million)
  - 7.2.6.2 Market size, by injection type, 2018 - 2032 (USD Million)
  - 7.2.6.3 Market size, by joint type, 2018 - 2032 (USD Million)
  - 7.2.6.4 Market size, by end use, 2018 - 2032 (USD Million)
7.3 Europe
- 7.3.1 Market size, by country, 2018 - 2032 (USD Million)
- 7.3.2 Market size, by injection type, 2018 - 2032 (USD Million)
- 7.3.3 Market size, by joint type, 2018 - 2032 (USD Million)
- 7.3.4 Market size, by end use, 2018 - 2032 (USD Million)
- 7.3.5 Germany
  - 7.3.5.1 Market size, by country, 2018 - 2032 (USD Million)
  - 7.3.5.2 Market size, by injection type, 2018 - 2032 (USD Million)
  - 7.3.5.3 Market size, by joint type, 2018 - 2032 (USD Million)
  - 7.3.5.4 Market size, by end use, 2018 - 2032 (USD Million)
- 7.3.6 UK
  - 7.3.6.1 Market size, by country, 2018 - 2032 (USD Million)
  - 7.3.6.2 Market size, by injection type, 2018 - 2032 (USD Million)
  - 7.3.6.3 Market size, by joint type, 2018 - 2032 (USD Million)
  - 7.3.6.4 Market size, by end use, 2018 - 2032 (USD Million)
- 7.3.7 France
  - 7.3.7.1 Market size, by country, 2018 - 2032 (USD Million)
  - 7.3.7.2 Market size, by injection type, 2018 - 2032 (USD Million)
  - 7.3.7.3 Market size, by joint type, 2018 - 2032 (USD Million)
  - 7.3.7.4 Market size, by end use, 2018 - 2032 (USD Million)
- 7.3.8 Italy
  - 7.3.8.1 Market size, by country, 2018 - 2032 (USD Million)
  - 7.3.8.2 Market size, by injection type, 2018 - 2032 (USD Million)
  - 7.3.8.3 Market size, by joint type, 2018 - 2032 (USD Million)
  - 7.3.8.4 Market size, by end use, 2018 - 2032 (USD Million)
- 7.3.9 Spain
  - 7.3.9.1 Market size, by country, 2018 - 2032 (USD Million)
  - 7.3.9.2 Market size, by injection type, 2018 - 2032 (USD Million)
  - 7.3.9.3 Market size, by joint type, 2018 - 2032 (USD Million)
  - 7.3.9.4 Market size, by end use, 2018 - 2032 (USD Million)
7.4 Asia Pacific
- 7.4.1 Market size, by country, 2018 - 2032 (USD Million)
- 7.4.2 Market size, by injection type, 2018 - 2032 (USD Million)
- 7.4.3 Market size, by joint type, 2018 - 2032 (USD Million)
- 7.4.4 Market size, by end use, 2018 - 2032 (USD Million)
- 7.4.5 China
  - 7.4.5.1 Market size, by country, 2018 - 2032 (USD Million)
  - 7.4.5.2 Market size, by injection type, 2018 - 2032 (USD Million)
  - 7.4.5.3 Market size, by joint type, 2018 - 2032 (USD Million)
  - 7.4.5.4 Market size, by end use, 2018 - 2032 (USD Million)
- 7.4.6 Japan
  - 7.4.6.1 Market size, by country, 2018 - 2032 (USD Million)
  - 7.4.6.2 Market size, by injection type, 2018 - 2032 (USD Million)
  - 7.4.6.3 Market size, by joint type, 2018 - 2032 (USD Million)
  - 7.4.6.4 Market size, by end use, 2018 - 2032 (USD Million)
- 7.4.7 India
  - 7.4.7.1 Market size, by country, 2018 - 2032 (USD Million)
  - 7.4.7.2 Market size, by injection type, 2018 - 2032 (USD Million)
  - 7.4.7.3 Market size, by joint type, 2018 - 2032 (USD Million)
  - 7.4.7.4 Market size, by end use, 2018 - 2032 (USD Million)
- 7.4.8 Australia
  - 7.4.8.1 Market size, by country, 2018 - 2032 (USD Million)
  - 7.4.8.2 Market size, by injection type, 2018 - 2032 (USD Million)
  - 7.4.8.3 Market size, by joint type, 2018 - 2032 (USD Million)
  - 7.4.8.4 Market size, by end use, 2018 - 2032 (USD Million)
- 7.4.9 South Korea
  - 7.4.9.1 Market size, by country, 2018 - 2032 (USD Million)
  - 7.4.9.2 Market size, by injection type, 2018 - 2032 (USD Million)
  - 7.4.9.3 Market size, by joint type, 2018 - 2032 (USD Million)
  - 7.4.9.4 Market size, by end use, 2018 - 2032 (USD Million)
7.5 Latin America
- 7.5.1 Market size, by country, 2018 - 2032 (USD Million)
- 7.5.2 Market size, by injection type, 2018 - 2032 (USD Million)
- 7.5.3 Market size, by joint type, 2018 - 2032 (USD Million)
- 7.5.4 Market size, by end use, 2018 - 2032 (USD Million)
- 7.5.5 Brazil
  - 7.5.5.1 Market size, by country, 2018 - 2032 (USD Million)
  - 7.5.5.2 Market size, by injection type, 2018 - 2032 (USD Million)
  - 7.5.5.3 Market size, by joint type, 2018 - 2032 (USD Million)
  - 7.5.5.4 Market size, by end use, 2018 - 2032 (USD Million)
- 7.5.6 Mexico
  - 7.5.6.1 Market size, by country, 2018 - 2032 (USD Million)
  - 7.5.6.2 Market size, by injection type, 2018 - 2032 (USD Million)
  - 7.5.6.3 Market size, by joint type, 2018 - 2032 (USD Million)
  - 7.5.6.4 Market size, by end use, 2018 - 2032 (USD Million)
- 7.5.7 Argentina
  - 7.5.7.1 Market size, by country, 2018 - 2032 (USD Million)
  - 7.5.7.2 Market size, by injection type, 2018 - 2032 (USD Million)
  - 7.5.7.3 Market size, by joint type, 2018 - 2032 (USD Million)
  - 7.5.7.4 Market size, by end use, 2018 - 2032 (USD Million)
7.6 Middle East and Africa
- 7.6.1 Market size, by country, 2018 - 2032 (USD Million)
- 7.6.2 Market size, by injection type, 2018 - 2032 (USD Million)
- 7.6.3 Market size, by joint type, 2018 - 2032 (USD Million)
- 7.6.4 Market size, by end use, 2018 - 2032 (USD Million)
- 7.6.5 South Africa
  - 7.6.5.1 Market size, by country, 2018 - 2032 (USD Million)
  - 7.6.5.2 Market size, by injection type, 2018 - 2032 (USD Million)
  - 7.6.5.3 Market size, by joint type, 2018 - 2032 (USD Million)
  - 7.6.5.4 Market size, by end use, 2018 - 2032 (USD Million)
- 7.6.6 Saudi Arabia
  - 7.6.6.1 Market size, by country, 2018 - 2032 (USD Million)
  - 7.6.6.2 Market size, by injection type, 2018 - 2032 (USD Million)
  - 7.6.6.3 Market size, by joint type, 2018 - 2032 (USD Million)
  - 7.6.6.4 Market size, by end use, 2018 - 2032 (USD Million)
- 7.6.7 UAE
  - 7.6.7.1 Market size, by country, 2018 - 2032 (USD Million)
  - 7.6.7.2 Market size, by injection type, 2018 - 2032 (USD Million)
  - 7.6.7.3 Market size, by joint type, 2018 - 2032 (USD Million)
  - 7.6.7.4 Market size, by end use, 2018 - 2032 (USD Million)

Chapter 8 Company Profiles

8.1 Competitive dashboard, 2022
8.2 Zimmer Biomet
- 8.2.1 Business overview
- 8.2.2 Financial data
- 8.2.3 Product landscape
- 8.2.4 Strategic outlook
- 8.2.5 SWOT analysis
8.3 Anika Therapeutics, Inc.
- 8.3.1 Business overview
- 8.3.2 Financial data
- 8.3.3 Product landscape
- 8.3.4 Strategic outlook
- 8.3.5 SWOT analysis
8.4 Bioventus
- 8.4.1 Business overview
- 8.4.2 Financial data
- 8.4.3 Product landscape
- 8.4.4 Strategic outlook
- 8.4.5 SWOT analysis
8.5 Sanofi
- 8.5.1 Business overview
- 8.5.2 Financial data
- 8.5.3 Product landscape
- 8.5.4 Strategic outlook
- 8.5.5 SWOT analysis
8.6 Pacira BioSciences (Flexion)
- 8.6.1 Business overview
- 8.6.2 Financial data
- 8.6.3 Product landscape
- 8.6.4 Strategic outlook
- 8.6.5 SWOT analysis
8.7 OrthogenRx
- 8.7.1 Business overview
- 8.7.2 Financial data
- 8.7.3 Product landscape
- 8.7.4 Strategic outlook
- 8.7.5 SWOT analysis
8.8 Pfizer
- 8.8.1 Business overview
- 8.8.2 Financial data
- 8.8.3 Product landscape
- 8.8.4 Strategic outlook
- 8.8.5 SWOT analysis
8.9 Ferring B.V.
- 8.9.1 Business overview
- 8.9.2 Financial data
- 8.9.3 Product landscape
- 8.9.4 Strategic outlook
- 8.9.5 SWOT analysis
8.10 Lifecore Biomedical
- 8.10.1 Business overview
- 8.10.2 Financial data
- 8.10.3 Product landscape
- 8.10.4 Strategic outlook
- 8.10.5 SWOT analysis
8.11 Wright Medical Group (Stryker)
- 8.11.1 Business overview
- 8.11.2 Financial data
- 8.11.3 Product landscape
- 8.11.4 Strategic outlook
- 8.11.5 SWOT analysis
8.12 Stryker
- 8.12.1 Business overview
- 8.12.2 Financial data
- 8.12.3 Product landscape
- 8.12.4 Strategic outlook
- 8.12.5 SWOT analysis
8.13 9.12. Emcyte Corporation
- 8.13.1 Business overview
- 8.13.2 Financial data
- 8.13.3 Product landscape
- 8.13.4 Strategic outlook
- 8.13.5 SWOT analysis
8.14 Arthrex
- 8.14.1 Business overview
- 8.14.2 Financial data
- 8.14.3 Product landscape
- 8.14.4 Strategic outlook
- 8.14.5 SWOT analysis